Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
13 août 2021 08h50 HE
|
Recro Pharma, Inc.
Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms ...
Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO
10 août 2021 07h00 HE
|
Recro Pharma, Inc.
EXTON, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Reports Second Quarter 2021 Financial Results
09 août 2021 16h05 HE
|
Recro Pharma, Inc.
Q2 2021 Highlighted by Revenues of $18.0 Million, an Increase of 16% Compared to Q2 2020 Revenue Multiple New Business Agreements Continue to Expand and Diversify Customer Base and Pipeline Company...
Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
02 août 2021 16h05 HE
|
Recro Pharma, Inc.
EXTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Appoints Erica Raether as Vice President of People, Culture and ESG
20 juil. 2021 07h00 HE
|
Recro Pharma, Inc.
EXTON, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Enters Development and Manufacturing Agreement With New Client
13 juil. 2021 07h00 HE
|
Recro Pharma, Inc.
GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
Recro Reports Inducement Grants for New Staff
07 juil. 2021 07h00 HE
|
Recro Pharma, Inc.
EXTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Appoints Laura L. Parks, Ph.D. to Board of Directors
16 juin 2021 07h00 HE
|
Recro Pharma, Inc.
EXTON, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Expands Capabilities for Growing Clinical Trial Services (CTS) Offerings
02 juin 2021 07h00 HE
|
Recro Pharma, Inc.
GAINESVILLE, Ga., June 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
Recro Enters Development Agreement With Astex Pharmaceuticals
18 mai 2021 07h00 HE
|
Recro Pharma, Inc.
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...